Filing Analysis
Utah Medical Products, Inc. filed an 8-K to announce its financial results for the three and six months ended June 30, 2026. The filing serves as a vehicle to provide earnings information via a press release.
📋 Key Facts
- Report date: July 23, 2026
- Reporting period: Three and six months ended June 30, 2026
- The filing includes financial information and forward-looking statements via Exhibit 99.1
- Signed by CEO Kevin L. Cornwell
Utah Medical Products, Inc. reported the results of its annual meeting of stockholders held on May 1, 2026. Stockholders elected two directors, ratified the company's independent auditor, and approved executive compensation on an advisory basis.
🚩 Red Flags
- High percentage of 'Withheld' votes for Director Ernst G. Hoyer, representing approximately 44.6% of the votes cast for that position (excluding broker non-votes).
- Significant 'Withheld' votes for Director James H. Beeson, representing approximately 28.8% of the votes cast for that position (excluding broker non-votes).
📋 Key Facts
- Annual meeting held on May 1, 2026.
- Ernst G. Hoyer elected as director with 1,330,333 'For' and 1,070,640 'Withheld' votes.
- James H. Beeson elected as director with 1,708,941 'For' and 692,032 'Withheld' votes.
- Haynie & Co. ratified as the independent public accounting firm for the fiscal year ending December 31, 2026.
- Advisory vote on executive compensation (Say-on-Pay) approved with 2,354,919 'For' votes.
- The company will continue to hold annual advisory votes on executive compensation.
Utah Medical Products, Inc. announced its financial results for the first quarter ended March 31, 2026, and provided forward-looking guidance for the remainder of the year. The disclosure was made via a press release furnished as an exhibit to the 8-K filing.
📋 Key Facts
- Financial results cover the three months ended March 31, 2026
- Filing date and report date are both April 23, 2026
- Information is furnished under Item 2.02 (Results of Operations and Financial Condition)
- Includes forward-looking statements relating to 2026 and beyond
Utah Medical Products, Inc. filed an 8-K to announce its financial results for the three and twelve months ended December 31, 2025. The filing serves as a placeholder to incorporate press release information regarding historical performance and forward-looking statements.
📋 Key Facts
- Report date: January 29, 2026
- Reporting period covers the three and twelve months ended December 31, 2025
- The filing includes financial information and forward-looking statements via Exhibit 99.1
- Signed by Kevin L. Cornwell, Chief Executive Officer
Utah Medical Products, Inc. announced the appointment of Kevin Timken to its Board of Directors and an increase in its regular quarterly cash dividend.
📋 Key Facts
- Board size increased from five to six members effective October 31, 2025.
- Kevin Timken appointed to the Board; will serve on Audit and Compensation and Benefits Committees.
- Mr. Timken received a grant of 10,000 stock options with an exercise price of $58.10 per share (vesting over four years).
- Quarterly cash dividend increased to $0.31 per share.
- Dividend record date is December 16, 2025; payable on January 5, 2026.
Utah Medical Products, Inc. filed an 8-K to announce the release of its quarterly financial results for the three and nine months ended September 30, 2025.
📋 Key Facts
- Report date: October 23, 2025
- Financial information covers the three and nine months ended September 30, 2025
- Includes forward-looking statements relating to 2025 and beyond
- Information furnished under Item 2.02 of Form 8-K
Utah Medical Products, Inc. filed an 8-K to announce the release of its financial results for the three and six months ended June 30, 2025. The filing includes forward-looking statements regarding the company's performance for the remainder of 2025.
📋 Key Facts
- Reported date: July 24, 2025
- Covers financial information for the three and six months ended June 30, 2025
- Includes forward-looking statements relating to 2025 and beyond
- Filed under Item 2.02 (Results of Operations and Financial Condition)
Utah Medical Products, Inc. reported the results of its annual meeting of stockholders held on May 2, 2025. The filing covers director elections, auditor ratification, and advisory votes on executive compensation.
🚩 Red Flags
- Director resignation attempt: The nominee (Carrie Leigh) tendered a resignation that the Board refused to accept, which may indicate internal governance friction or disagreement with board direction.
📋 Key Facts
- Carrie Leigh was elected to the Board of Directors with 665,574 'For' votes; however, she had tendered a resignation which the Board declined to accept.
- Haynie & Co. was ratified as the independent public accounting firm for the fiscal year ending December 31, 2025, with 3,148,121 'For' votes.
- Stockholders approved executive compensation on an advisory basis with 2,383,762 'For' votes.
- Ms. Leigh will serve a three-year term per Utah law until a successor is elected and qualified.
Utah Medical Products, Inc. filed an 8-K to announce its financial results for the three months ended March 31, 2025, and provided forward-looking guidance for the remainder of 2025.
📋 Key Facts
- Report date: April 29, 2025
- Reporting period: Three months ended March 31, 2025
- The filing includes financial information and forward-looking statements for 2025 via Exhibit 99.1.
- Signed by Kevin L. Cornwell, Chief Executive Officer.
Utah Medical Products, Inc. filed an 8-K to announce its financial results for the three and twelve months ended December 31, 2024. The filing includes forward-looking statements regarding the company's performance in 2024 and beyond.
📋 Key Facts
- Report date: January 28, 2025
- Reporting period: Three and twelve months ended December 31, 2024
- The filing includes financial information via a press release (Exhibit 99.1)
- Includes forward-looking statements regarding 2024 performance and beyond
Utah Medical Products, Inc. announced the appointment of Carrie Leigh to its Board of Directors and an increase in its quarterly cash dividend. Notably, Ms. Leigh is the daughter of the company's CEO, Kevin Cornwell.
🚩 Red Flags
- Related-party transaction: Appointment of the CEO's daughter to the Board of Directors and granting of stock options.
- Potential governance concern regarding independence on the Compensation and Benefits committee due to familial relationship with the CEO.
📋 Key Facts
- Board size increased from five to six members.
- Carrie Leigh appointed to the Board and the Compensation and Benefits committee.
- Ms. Leigh is the daughter of CEO Kevin Cornwell (Related Party).
- Ms. Leigh granted 10,000 stock options with an exercise price of $64.09 per share, vesting over four years.
- Quarterly cash dividend increased to $0.305 per share, payable January 3, 2025.
- Record date for the dividend is December 16, 2024.
Utah Medical Products, Inc. filed an 8-K to announce the release of its financial results for the three and nine months ended September 30, 2024. The filing serves as a formal notice that earnings data and forward-looking guidance have been made public via a press release.
📋 Key Facts
- Reporting period: Three and nine months ended September 30, 2024.
- Filing date: October 29, 2024.
- The filing includes financial information and forward-looking statements for 2024 and beyond via Exhibit 99.1.
Utah Medical Products, Inc. filed an 8-K to announce the release of its financial results for the three and six months ended June 30, 2024. The filing serves as a vehicle to furnish quarterly earnings data via a press release.
📋 Key Facts
- Reporting period: Three and six months ended June 30, 2024.
- Filing date: July 25, 2024.
- The filing includes forward-looking statements relating to 2024 and beyond.
- Financial information is provided via Exhibit 99.1 (Press Release).
Utah Medical Products, Inc. reported the results of its annual meeting of stockholders held on May 3, 2024. The filing details director elections, auditor ratification, and advisory votes on executive compensation.
🚩 Red Flags
- Paul O. Richins received a high number of withheld votes (1,833,586) relative to his 'For' votes (907,483), indicating significant shareholder dissatisfaction or lack of support for this specific candidate.
- The Board's decision to reject Mr. Richins' resignation may indicate internal governance friction or a desire to maintain board composition despite shareholder sentiment.
📋 Key Facts
- Kevin L. Cornwell was elected as a director with 1,436,389 votes 'For'.
- Paul O. Richins was elected as a director with 907,483 votes 'For', despite having significantly more withheld votes (1,833,586) than 'For' votes.
- Haynie & Co. was ratified as the independent public accounting firm for the fiscal year ending December 31, 2024.
- Stockholders approved executive compensation on an advisory basis with 2,662,106 votes 'For'.
- The Board of Directors declined to accept the resignation tendered by Paul O. Richins.
Utah Medical Products, Inc. filed an 8-K to announce the release of its financial results for the three months ended March 31, 2024. The filing includes forward-looking statements regarding the company's performance in 2024 and beyond.
📋 Key Facts
- Report date: April 25, 2024
- Reporting period: Three months ended March 31, 2024
- The filing includes financial information provided via a press release (Exhibit 99.1)
- Includes forward-looking statements regarding 2024 and beyond
Utah Medical Products, Inc. filed an 8-K to announce its financial results for the three and twelve months ended December 31, 2023. The filing serves as a vehicle to furnish earnings information via a press release.
📋 Key Facts
- Report date: January 30, 2024
- Reporting period: Three and twelve months ended December 31, 2023
- The filing includes financial information and forward-looking statements via Exhibit 99.1
- Signed by Kevin L. Cornwell, Chief Executive Officer